SYK and lymphoma: In our current study, we showed an increase in SYK phosphorylation in LMP2A-positive MYC-induced lymphoma and that targeting SYK with a novel SYK inhibitor, TAK-659, completely inhibited splenomegaly and tumorigenesis.